Functional Screening and Transcriptomic Analysis Identify Novel Druggable Dependencies and Immunotherapy Targets in Desmoplastic Small Round Cell Tumor
RNA-seq (gene expression) · human · 124 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 124 samples: 62 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE264741_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1104112 and SRA study SRP503731. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 124 samples.
How we read this: 62 replicated groups read from 124 sample titles; they account for 124 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8226922 MSK_4746__R1 MSK_4746
- GSM8226923 MSK_4746__R2 MSK_4746
- GSM8226924 MSK_4753__R1 MSK_4753
- GSM8226925 MSK_4753__R2 MSK_4753
- GSM8226926 MSK_4781__R1 MSK_4781
- GSM8226927 MSK_4781__R2 MSK_4781
- GSM8226928 MSK_4801__R1 MSK_4801
- GSM8226929 MSK_4801__R2 MSK_4801
- GSM8226930 MSK_4807B_R1 MSK_4807B
- GSM8226931 MSK_4807B_R2 MSK_4807B
- GSM8226932 MSK_4807C_R1 MSK_4807C
- GSM8226933 MSK_4807C_R2 MSK_4807C
- GSM8226934 MSK_4807D_R1 MSK_4807D
- GSM8226935 MSK_4807D_R2 MSK_4807D
- GSM8226936 MSK_4832__R1 MSK_4832
- GSM8226937 MSK_4832__R2 MSK_4832
- GSM8226938 MSK_4892__R1 MSK_4892
- GSM8226939 MSK_4892__R2 MSK_4892
- GSM8226940 MSK_4895A_R1 MSK_4895A
- GSM8226941 MSK_4895A_R2 MSK_4895A
- GSM8226942 MSK_4895B_R1 MSK_4895B
- GSM8226943 MSK_4895B_R2 MSK_4895B
- GSM8226944 MSK_4915A_R1 MSK_4915A
- GSM8226945 MSK_4915A_R2 MSK_4915A
- GSM8226946 MSK_4915C_R1 MSK_4915C
- GSM8226947 MSK_4915C_R2 MSK_4915C
- GSM8226948 MSK_4916__R1 MSK_4916
- GSM8226949 MSK_4916__R2 MSK_4916
- GSM8226950 MSK_4918__R1 MSK_4918
- GSM8226951 MSK_4918__R2 MSK_4918
- GSM8226952 MSK_4919__R1 MSK_4919
- GSM8226953 MSK_4919__R2 MSK_4919
- GSM8226954 MSK_4921__R1 MSK_4921
- GSM8226955 MSK_4921__R2 MSK_4921
- GSM8226956 MSK_4927__R1 MSK_4927
- GSM8226957 MSK_4927__R2 MSK_4927
- GSM8226958 MSK_4931__R1 MSK_4931
- GSM8226959 MSK_4931__R2 MSK_4931
- GSM8226960 MSK_4943__R1 MSK_4943
- GSM8226961 MSK_4943__R2 MSK_4943
+ 84 more — browse all 124 samples with per-sample file links →
- GSE271689 Enhancing Immunotherapy Outcomes: Spatial Multi-Omics Predictive Models for Non-Small Cell Lung Cancer 586 samples shares immunotherapy, small
- GSE311200 Comprehensive analysis of the correlation between circulating biomarkers and tumor-immune microenvironment in advanced or recurrence non-small cell lung cancer in various treatment options, i.e., immunotherapy, EGFR TKI, and chemotherapy 41 samples shares immunotherapy, small
- GSE318521 An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma [ATAC-seq] 24 samples shares dependencies, targets
- GSE235093 Pre-existing skin-resident CD8 and γδ T cell circuits mediate immune response in Merkel cell carcinoma and Predict immunotherapy efficacy 333 samples shares immunotherapy
- GSE235090 Pre-existing skin-resident CD8 and γδ T cell circuits mediate immune response in Merkel cell carcinoma and Predict immunotherapy efficacy [scRNA_tissue] 192 samples shares immunotherapy
- GSE307931 Circulating transcriptome analysis finds gene signatures and immune cell activation and abundance predict response to immunotherapy in bladder cancer 164 samples shares immunotherapy
- GSE275078 In vitro drug screening of RAF/MEK/ERK Inhibitors in combination with Autophagy inhibition in the context of two PDA Cell Lines 136 samples shares screening
- GSE253173 Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy II 100 samples shares immunotherapy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.